209 related articles for article (PubMed ID: 29772482)
1. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub-analysis of HIJ-PROPER.
Yamaguchi J; Kawada-Watanabe E; Koyanagi R; Arashi H; Sekiguchi H; Nakao K; Tobaru T; Tanaka H; Oka T; Endo Y; Saito K; Uchida T; Matsui K; Ogawa H; Hagiwara N
Atherosclerosis; 2018 Jul; 274():139-145. PubMed ID: 29772482
[TBL] [Abstract][Full Text] [Related]
2. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
Hagiwara N; Kawada-Watanabe E; Koyanagi R; Arashi H; Yamaguchi J; Nakao K; Tobaru T; Tanaka H; Oka T; Endoh Y; Saito K; Uchida T; Matsui K; Ogawa H
Eur Heart J; 2017 Aug; 38(29):2264-2276. PubMed ID: 28430910
[TBL] [Abstract][Full Text] [Related]
3. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER).
Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N
J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705
[TBL] [Abstract][Full Text] [Related]
4. The Effects of Lipid-Lowering Therapy on Serum Eicosapentaenoic Acid to Arachidonic Acid Ratio: An HIJ-PROPER Sub-Analysis.
Arashi H; Yamaguchi J; Kawada-Watanabe E; Otsuki H; Sekiguchi H; Ogawa H; Hagiwara N
J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):548-555. PubMed ID: 32567339
[TBL] [Abstract][Full Text] [Related]
5. Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ-PROPER.
Arashi H; Yamaguchi J; Kawada-Watanabe E; Koyanagi R; Sekiguchi H; Mori F; Haruta S; Ishii Y; Murasaki S; Suzuki K; Yamauchi T; Ogawa H; Hagiwara N
J Am Heart Assoc; 2019 Aug; 8(16):e012953. PubMed ID: 31390907
[TBL] [Abstract][Full Text] [Related]
6. Baseline low-density lipoprotein cholesterol predicts the benefit of adding ezetimibe on statin in statin-naïve acute coronary syndrome.
Im J; Kawada-Watanabe E; Yamaguchi J; Arashi H; Otsuki H; Matsui Y; Sekiguchi H; Fujii S; Mori F; Ogawa H; Hagiwara N
Sci Rep; 2021 Apr; 11(1):7480. PubMed ID: 33820931
[TBL] [Abstract][Full Text] [Related]
7. Targeting high-sensitivity C-reactive protein levels in acute coronary syndrome patients undergoing contemporary lipid-lowering therapy: a sub-analysis of the HIJ-PROPER trial.
Kawada-Watanabe E; Yamaguchi J; Sekiguchi H; Arashi H; Ogawa H; Hagiwara N
J Cardiol; 2020 May; 75(5):500-506. PubMed ID: 31699568
[TBL] [Abstract][Full Text] [Related]
8. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial.
Taguchi I; Iimuro S; Iwata H; Takashima H; Abe M; Amiya E; Ogawa T; Ozaki Y; Sakuma I; Nakagawa Y; Hibi K; Hiro T; Fukumoto Y; Hokimoto S; Miyauchi K; Yamazaki T; Ito H; Otsuji Y; Kimura K; Takahashi J; Hirayama A; Yokoi H; Kitagawa K; Urabe T; Okada Y; Terayama Y; Toyoda K; Nagao T; Matsumoto M; Ohashi Y; Kaneko T; Fujita R; Ohtsu H; Ogawa H; Daida H; Shimokawa H; Saito Y; Kimura T; Inoue T; Matsuzaki M; Nagai R
Circulation; 2018 May; 137(19):1997-2009. PubMed ID: 29735587
[TBL] [Abstract][Full Text] [Related]
9. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Giugliano RP; Cannon CP; Blazing MA; Nicolau JC; Corbalán R; Špinar J; Park JG; White JA; Bohula EA; Braunwald E;
Circulation; 2018 Apr; 137(15):1571-1582. PubMed ID: 29263150
[TBL] [Abstract][Full Text] [Related]
10. Lower levels of high-density lipoprotein cholesterol are associated with increased cardiovascular events in patients with acute coronary syndrome.
Nakazawa M; Arashi H; Yamaguchi J; Ogawa H; Hagiwara N
Atherosclerosis; 2020 Jun; 303():21-28. PubMed ID: 32474302
[TBL] [Abstract][Full Text] [Related]
11. Ezetimibe + statin: insufficient benefit.
Prescrire Int; 2016 Oct; 25(175):245-246. PubMed ID: 30645833
[TBL] [Abstract][Full Text] [Related]
12. Effect of Ezetimibe + Pitavastatin on Cardiovascular Outcomes in Patients with ST-Segment Elevation Myocardial Infarction (from the HIJ-PROPER Study).
Otsuki H; Arashi H; Yamaguchi J; Kawada-Watanabe E; Ogawa H; Hagiwara N
Am J Cardiol; 2020 Oct; 132():15-21. PubMed ID: 32773226
[TBL] [Abstract][Full Text] [Related]
13. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.
Gitt AK; Lautsch D; Ferrières J; De Ferrari GM; Vyas A; Baxter CA; Bash LD; Ashton V; Horack M; Almahmeed W; Chiang FT; Poh KK; Brudi P; Ambegaonkar B
Atherosclerosis; 2017 Nov; 266():158-166. PubMed ID: 29028484
[TBL] [Abstract][Full Text] [Related]
14. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
15. Predictive Value of Baseline High-Sensitivity C-Reactive Protein Level and Renal Function for Patients With Acute Coronary Syndrome Undergoing Aggressive Lipid-Lowering Therapy: A Subanalysis of HIJ-PROPER.
Kawada-Watanabe E; Yamaguchi J; Kanbayashi K; Sekiguchi H; Arashi H; Ogawa H; Hagiwara N
Am J Cardiol; 2018 Dec; 122(11):1817-1823. PubMed ID: 30270178
[TBL] [Abstract][Full Text] [Related]
16. Effects of Statin versus the Combination of Ezetimibe plus Statin on Serum Lipid Absorption Markers in Patients with Acute Coronary Syndrome.
Watanabe E; Yamaguchi J; Arashi H; Ogawa H; Hagiwara N
J Lipids; 2015; 2015():109158. PubMed ID: 25815213
[TBL] [Abstract][Full Text] [Related]
17. Effect of Aggressive Lipid-Lowering Therapy in Single-Vessel vs. Multivessel Coronary Artery Disease Patients With Acute Coronary Syndrome - Heart Institute of Japan-Proper Level of Lipid Lowering With Pitavastatin and Ezetimibe in Acute Coronary Syndrome (HIJ-PROPER) Substudy.
Ogiso M; Yamaguchi J; Kawada-Watanabe E; Koyanagi R; Sekiguchi H; Sakamoto T; Iguchi N; Tanaka H; Okada H; Ota Y; Jujo K; Fujii S; Ogawa H; Hagiwara N
Circ Rep; 2020 Jan; 2(2):128-134. PubMed ID: 33693218
[No Abstract] [Full Text] [Related]
18. Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis.
Mahajan K; Nagendra L; Dhall A; Dutta D
Eur J Intern Med; 2024 Jun; 124():99-107. PubMed ID: 38336550
[TBL] [Abstract][Full Text] [Related]
19. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
[TBL] [Abstract][Full Text] [Related]
20. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Suzuki T; Ueda S; Fukami K; Okuda S; Yamagishi S
Pharmacol Res; 2010 Jan; 61(1):58-61. PubMed ID: 19666118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
